Energised by a debt recast, Chennai-based Orchid Chemicals and Pharmaceuticals is looking at the West to return to profitability.
Hit by working capital constraints and high interest costs, the company posted a loss of ₹530.23 crore in the 18 months ended September 2013, compared with a profit of ₹103.11 crore in fiscal 2011-12.
Non-antibiotic formulations constitute a $16-billion market in the US and the company has also filed for licences to market 30 generic drugs in the European Union. “The growth in the non-antibiotic formulations will come through product launches over the next two-three years in these markets,” K Raghavendra Rao, Chairman and Managing Director, told shareholders at the company’s AGM here. A US subsidiary for marketing its drugs and a research unit, Bexel Pharmaceuticals Inc, will help widen Orchid’s presence in the US.
More Like This
Published on March 20, 2014
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.